Abstract
Introduction
The study of the t (9;22) 
translocation associated with chronic myelogenous leukaemia (CML) led to the discovery of the first protein tyrosine kinase (TK) fusion gene, BCR-ABL, more than 25 years ago (reviewed in
Ref. [1] ). Later on, several other TK fusion genes were identified in haematological malignancies. They involved both cytosolic TK, such as JAK2 or SYK, and receptor TK, including PDGFRA, PDGFRB, FGFR1 and ALK [2, 3] . Tyrosine kinase fusion genes were found in solid tumours at a lower rate, which may be underestimated due to the lack of systematic cytogenetic analysis. Nevertheless, papillary thyroid carcinoma frequently harbours activated RET fusion genes and the EML4-ALK rearrangement is found in about 5% of non-small cell lung carcinomas [4, 5] .
Among the 90 TK genes that are present in the human genome, at least 14 were found rearranged with various partner genes in cancer (Fig. 1 , Table S1 and databases, Refs. [6, 7] ). Some fusions are tightly associated with a particular neoplasm, while others were only reported in one patient. A few more TK genes have the potential of forming activated fusion oncogenes, even though they have not been found in cancer patients yet (Table S1 and Refs. [8, 9] Tyrosine kinase domains share a conserved bilobal structure.
The N-terminal lobe binds adenosine-5'-triphosphate (ATP), while the active site is at the hinge between the two lobes. In the inactive conformation, the activation loop of the C-terminal lobe prevents substrate binding. Upon phosphorylation, this loop undergoes an important conformational change that allows substrate binding and phosphate transfer from ATP. The phosphorylation of the activation loop of ABL is normally mediated by another kinase. In the case of receptor TKs and JAKs, trans-autophosphorylation is triggered by dimerization and conformational changes induced by ligand binding to the extracellular part of the receptor. In addition, inhibitory domains that keep the TK domain silent in the absence of stimulus have been identified in most TK proteins. The oncogenic activation of TK fusions invariably involves enforced dimerization and/or inactivation of inhibitory domains, as discussed later. The partner gene fused to the TK gene plays an important role by controlling the oligomerization and the expression level of the fusion oncoprotein. Additional roles of the partners will also be discussed in this review.

Tyrosine kinase inhibitors
Achieving specific inhibition of TK enzymes with ATP competitors was initially though to be unlikely. The success of imatinib, designed as a selective inhibitor of ABL, thus came as a surprise. Leukaemic cells survival turned out to be highly dependent on BCR-ABL signalling, a process sometimes referred to as oncogene addiction [10] . Imatinib monotherapy is now the first line treatment of CML and induces long-term remission in the majority of patients, although resistance does occur in part due to BCR-ABL mutations [1] . Imatinib is also effective in BCR-ABL-positive acute lymphoblastic leukaemia but the rate of relapse is much higher than in CML [11] . Novel [12] . Other types of inhibitors will be discussed later.
Imatinib is an even more potent inhibitor of platelet-derived growth factor (PDGF) receptors. Accordingly, myeloproliferative neoplasms carrying a PDGF receptor fusion are extremely sensitive to low-dose imatinib [13] . These major successes have prompted the development of inhibitors of other TK, such as FGFR1, JAK2 and ALK (Table 1) . Some of these molecules are now tested in clinical trials (for a review, see Refs. [14, 15] ). Remarkably, the ALK inhibitor crizotinib produced promising results in a subset of non-small cell lung cancer patients that are positive for the EML4-ALK rearrangement [5] . Again, resistant ALK mutations were identified in treated patients [15] 
Inhibitory domain deletion
As mentioned earlier, most TK proteins comprise inhibitory domains that dampen the kinase activity in the absence of stimuli by stabilizing the inactive conformation ( Fig. 1 In PDGF receptors, the C-terminal tail was also shown to play a negative role [59, 60] [64, 65] [3] . Although this truncation is not enough to activate JAK2 [69] , it remains to be tested whether it increases the activity of the oligomerized hybrid.
. We observed that the deletion of this domain in ETV6-PDGFRB enhances its transformation potential (unpublished data). The N-terminal part of ABL and ABL2 (also called ARG) contain a myristoylation site, one SH2 and one SH3 domain. In the inactive conformation, these domains are assembled in an autoinhibited structure, in which they function as a clamp that switches off the kinase activity [1]. A partial deletion of these domains is enough to activate ABL. In particular, the myristoyl group binds to a hydrophobic pocket within the kinase domain [61]. The N-terminal myristoylation site is lost in all ABL and ARG fusions, contributing to constitutive activation. This mechanism does not seem to be conserved in other cytosolic TK. Interestingly, a ligand that mimics a myristoyl group and binds to the hydrophobic pocket acts as an allosteric inhibitor of BCR-ABL by restoring its inactive conformation [62]. Such molecules constitute a novel class of TK inhibitors (Table 1). Interestingly, a synergy between ATP competitors, oligomerization inhibitors and allosteric inhibitors has been observed and may be useful to overcome resistance [40, 62]. In addition, the SH3 and SH2 domains are deleted in a minority of ABL fusion products, including SFPQ-ABL and RCSD1-ABL, but not in BCR-ABL [63]. Remarkably, the SH2 domain of BCR-ABL is required to induce CML but not a lymphoid disease in mice
In [73] . Similarly, NUP214-ABL and BCR-ABL do not phosphorylate exactly the same set of peptide substrates [74] . Differences were also reported between fusion and wild-type PDGF receptors, in particular regarding signal transducer and activator of transcription (STAT) activation [75] .
conclusion, the deletion of inhibitory domains is frequent among TK fusion products and contributes to the constitutive TK activity. This is however not an absolute requirement as oligomerization by itself can destabilize the autoinhibited TK conformation. In a number of cases, the combination of oligomerization and deletion of inhibitory motifs was shown to synergistically enhance the kinase activity.
Signalling pathways
Cell transformation resulting from TK hybrids expression is the consequence of the activation of signalling pathways that control cell proliferation and apoptosis inhibition. Most TK fusions, like their wild-type counterparts, use a common set of signalling pathways: phosphatidylinositol-3-kinase (PI3K) and its downstream effector PKB, the MAP kinase pathways and the transcription factors signal transducer and activator of transcription (STAT) and NF-B. Activating mutations in RAS, RAF or PI3K, which are commonly found in cancer, and TK fusions are mutually exclusive, indicating that they constitutively activate signalling pathways in a similar manner and that there is no further advantage for tumour cells in combining such mutations. The importance of these cascades in cancer has been extensively reviewed and it is impossible to mention here all the reports that studied signalling by TK fusions (reviewed in Refs. [1, 70-72]). Tyrosine kinase fusions activate aberrant signalling pathways compared to the normal TK form, which may contribute to oncogene addiction. For instance, Voss et al. provided evidence that ABL oncogenic hybrids (BCR-ABL and ETV6-ABL) harbour catalytic specificities that activate distinct signalling pathways compare to wild-type ABL
STAT transcription factors are activated by most TK fusions [1, 2, [76] [77] [78] [79, 80] , and for FIP1L1-PDGFRA in human primary haematopoietic cells [81] . ZNF198-FGFR1 also activates STAT5 leading to cell cycle progression and apoptosis inhibition [82] . [83, 84] . The Y177F mutation in BCR-ABL abolishes GRB2 binding without affecting the kinase activity of ABL [83, 84] . In a mouse bone marrow transplantation model of CML, the Y177F mutant showed a reduced ability to induce a myeloproliferative disorder. Accordingly, the targeted deletion of GAB2 or PI3K␦, the major haematopoietic PI3K isoform, reduces the leukaemic potential of BCR-ABL-expressing cells [85, 86] . [87] . In this respect, a number of inhibitors of the MAP kinase and PI3K pathways have now entered the clinic and may be tested in cancers associated with rearrangement of TK genes. (Fig. 4). This is illustrated by the FIP1L1 part of FIP1L1- [91] .
. It was demonstrated that STAT5 is particularly important for leukaemogenesis induced by BCR-ABL and ETV6-PDGFRB in mice
MAP kinases and PI3K are other mediators shared by TK fusions. Most studies addressed the role of these pathways using pharmalogical inhibitors whose specificity has been largely debated. Nevertheless, additional experiments have confirmed their importance. In BCR-ABL, tyrosine 177 within the BCR part is phosphorylated and binds to GRB2, which in turn recruits GAB2 (GRB2-associated binding protein 2) and Son of Sevenless homolog (SOS), a guanine-nucleotide exchanger of RAS. The phosphorylation-dependent formation of this complex leads to the activation of RAS and PI3K
Even though targeting the TK fusion itself seems more efficient than targeting downstream signalling, combining both approaches may be a way to overcome resistance. For instance, MAP kinase pathway inhibitors sensitize imatinib-resistant CML cells to the BCR-ABL inhibitor dasatinib
Recruitment of additional molecules by the fusion partner
Another example of dominant negative effect of the fusion is ETV6-FRK, which was shown to inhibit ETV6-mediated transcriptional repression [92] . This was also demonstrated for the fusion of the non-muscular tropomyosine TPM3 with ALK. [93] . It was demonstrated that TPM3-ALK has the ability to interact with endogenous tropomyosine, possibly impairing tropomyosine cellular function and actin cytoskeleton organization [94] .
TPM3-ALK expressing cells displayed a highest migratory and invasive capacities compared to cells expressing other ALK fusions
Although [95] . Chaperones are also interacting with BCR-ABL and NPM-ALK as discussed later, but it is not clear whether they interact with the partner part in these cases. 
Stabilization and degradation
As already stated earlier, the level of TK expression is critical for cell transformation [96] . Decreasing degradation of the oncoprotein is one way to achieve a higher expression. Receptor [99] . HSP90 also modulates maturation and activity of NPM-ALK fusion oncoprotein [100] . When association between HSP90 and NPM-ALK is impaired the fusion protein is rapidly degraded through HSP70-assisted ubiquitin-dependent proteasomal degradation [101] . We previously mentioned that ZNF198-FGFR1 also bind to chaperones [95] .
Because of its large client repertoire, including TKs, anticancer agents were developed against HSP90, including geldanamycin derivatives, and are now being tested in clinical trials [102] 
